Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
  • Publication number: 20150143582
    Abstract: The invention relates to a pathogen-inducible synthetic promoter which is suitable for regulating the transcription of a nucleic acid, and includes a minimal promoter, characterized in that the minimal promoter includes a sequence motif a) dbrmwa or b) twcccmt which is disposed downstream from a TATA region and in front of a transcription starting point which is located on the minimal promoter and at which transcription of the nucleic acid to be regulated starts.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 21, 2015
    Inventor: Klaus Schmidt
  • Publication number: 20150133528
    Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 14, 2015
    Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital
    Inventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
  • Publication number: 20150135362
    Abstract: The invention provides DNA molecules and constructs, including their nucleotide sequences, useful for modulating gene expression in plants and plant cells. Transgenic plants, plant cells, plant parts, seeds, and commodity products comprising the DNA molecules operably linked to heterologous transcribable polynucleotides are also provided, as are methods of their use.
    Type: Application
    Filed: May 11, 2012
    Publication date: May 14, 2015
    Applicant: MONSANTO TECHNOLOGY LLC
    Inventors: Stanislaw Flasinski, Barrett C. Foat, Mohammed Oufattole, Randall W. Shultz, Xiaoping Wei, Wei Wu, Shiaw-Pyng Yang
  • Publication number: 20150135368
    Abstract: The invention relates to promoters for stress-induced expression in plants as well as to methods for rendering any given promoter into a stress-inducible promoter. The invention further relates to promoter sequences produced with such methods and their use for stress-induced gene expression.
    Type: Application
    Filed: February 28, 2013
    Publication date: May 14, 2015
    Applicant: BASFPlant Scence Company GmbH
    Inventors: Anke Eisenmann, Lorenz Bülow, Yves Hatzfeld, Zhongyi Zhou
  • Patent number: 9029523
    Abstract: The present invention provides DNA molecules that constitute fragments of the genome of a plant, and polypeptides encoded thereby. The DNA molecules are useful for specifying a gene product in cells, either as a promoter or as a protein coding sequence or as an UTR or as a 3? termination sequence, and are also useful in controlling the behavior of a gene in the chromosome, in controlling the expression of a gene or as tools for genetic mapping, recognizing or isolating identical or related DNA fragments, or identification of a particular individual organism, or for clustering of a group of organisms with a common trait. One of ordinary skill in the art, having this data, can obtain cloned DNA fragments, synthetic DNA fragments or polypeptides constituting desired sequences by recombinant methodology known in the art or described herein.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: May 12, 2015
    Assignee: Ceres, Inc.
    Inventors: Nickolai Alexandrov, Nestor Apuya, Vyacheslav Brover, Jean-Baptiste Dumas, Yiwen Fang, Ken Feldmann, Diane Jofuku, Edward A. Kiegle, Bill Kimmerly, Shing Kwok, Peter Mascia, Jack Okamuro, Roger Pennell, Richard Schneeberger, Tatiana Tatarinova, Wayne Volkmuth
  • Patent number: 9029339
    Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: May 12, 2015
    Assignee: CoDa Therapeutics, Inc.
    Inventors: David Laurence Becker, Colin Richard Green, Bradford J. Duft
  • Publication number: 20150128302
    Abstract: The present invention provides compositions and methods for regulating expression of heterologous nucleotide sequences in a plant. Compositions are novel nucleotide sequences for a constitutive regulatory element isolated from sorghum. A method for expressing a heterologous nucleotide sequence in a plant using the regulatory sequences disclosed herein is provided. The method comprises transforming a plant cell to comprise a heterologous nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed plant from the transformed plant cell.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 7, 2015
    Inventor: Shane Abbitt
  • Publication number: 20150126438
    Abstract: The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by detecting the levels of a novel isoform of ChREBP, termed ChREBP ?. The invention also provides nucleic acids, proteins, reporter constructs based on ChREBP ? and methods of identifying one or more agents that modulate the expression of a ChREBP ? target gene.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 7, 2015
    Inventors: Mark A. Herman, Barbara B. Kahn
  • Patent number: 9024005
    Abstract: The present invention relates to complexes of transcription factor decoys, their delivery to bacteria and their formulation. In particular, the present invention resides in an antibacterial complex comprising a nucleic acid sequence and one or more delivery moieties selected from quaternary amine compounds; bis-aminoalkanes and unsaturated derivatives thereof, wherein the amino component of the aminoalkane is an amino group forming part of a heterocyclic ring; and an antibacterial peptide.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 5, 2015
    Assignee: Procarta Biosystems Ltd
    Inventor: Michael McArthur
  • Publication number: 20150121568
    Abstract: Compositions and methods for regulating expression of heterologous nucleotide sequences in a plant are provided. Compositions include nucleotide sequences for an Arabidopsis thaliana (AT SVL3) promoter. Also provided is a method for expressing a heterologous nucleotide sequence in a plant using a promoter sequence disclosed herein.
    Type: Application
    Filed: January 15, 2015
    Publication date: April 30, 2015
    Inventors: Mark Alan Chamberlin, Shai Joshua Lawitt
  • Patent number: 9018002
    Abstract: A method to generate siRNAs in vivo is described, as are constructs and compositions useful in the method. The method does not depend on the use of DNA or synthetic constructs that contain inverted duplications or dual promoters so as to form perfect or largely double-stranded RNA. Rather, the method depends on constructs that yield single-stranded RNA transcripts, and exploits endogenous or in vivo-produced miRNAs or siRNAs to initiate production of siRNAs. The miRNAs or siRNAs guide cleavage of the transcript and set the register for production of siRNAs (usually 21 nucleotides in length) encoded adjacent to the initiation cleavage site within the construct. The method results in specific formation of siRNAs of predictable size and register (phase) relative to the initiation cleavage site. The method can be used to produce specific siRNAs in vivo for inactivation or suppression of one or more target genes or other entities, such as pathogens.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 28, 2015
    Assignee: State of Oregon acting by and through the State Board of Higher Education on behalf of Oregon State University
    Inventors: James C. Carrington, Edwards Allen
  • Patent number: 9018365
    Abstract: The invention provides methods and compositions for attaching oligonucleotide tags to polynucleotides for the purpose of carrying out analytical assays in parallel and for decoding the oligonucleotide tags of polynucleotides selected in such assays. Words, or subunits, of oligonucleotide tags index submixtures in successively more complex sets of submixtures (referred to herein as “tiers” of submixtures) that a polynucleotide goes through while successive words are added to a growing tag. By identifying each word of an oligonucleotide tag, a series of submixtures is identified including the first submixture that contains only a single polynucleotide, thereby providing the identity of the selected polynucleotide. The analysis of the words of an oligonucleotide tag can be carried out in parallel, e.g.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: April 28, 2015
    Assignee: Population Genetics Technologies Ltd
    Inventor: Sydney Brenner
  • Patent number: 9018182
    Abstract: Provided are tumor-specific promoters, oncolytic virus vectors and a pharmaceutical composition comprising the virus vector. The virus vector comprising the novel tumor-specific promoter shows excellent oncolytic effects on tumor cells, and thus it is useful for treating a cancer.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: April 28, 2015
    Assignees: Green Cross Corporation, Mogam Biotechnology Research Institute, Industry-Academic Cooperation Foundation, Yonsei University
    Inventors: Daekyung Koh, Seongtae Yun, Kyuhyun Lee, Hong-Kyu Lee, Mihee Hwang, Chae-Ok Yun, Eui-Cheol Jo
  • Patent number: 9017938
    Abstract: This invention concerns the use of MicroRNA-199b-5p in medical and diagnostic fields. Particularly, this invention concerns the use of the miR199b-5p in the anti-cancer therapy and as a histophatological and metastasis marker.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: April 28, 2015
    Assignee: Advanced Accelerator Applications
    Inventor: Massimo Zollo
  • Publication number: 20150111957
    Abstract: An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.
    Type: Application
    Filed: September 24, 2014
    Publication date: April 23, 2015
    Inventors: Eyal Breitbart, Livnat Bangio, Reshef Tal
  • Publication number: 20150111954
    Abstract: The invention provides compositions and methods for regulating microRNA (miRNA) biogenesis. The invention also relates to compositions and methods for treating or preventing cancer in a subject in need thereof.
    Type: Application
    Filed: November 9, 2012
    Publication date: April 23, 2015
    Inventors: Piotr Sliz, Yunsun NAM
  • Patent number: 9012720
    Abstract: A polynucleotide isolated from soybean plants capable of initiating transcription and with sequence identity to SEQ ID No. 1 is provided. In some aspects, the polynucleotide has sequence identity to SEQ ID No. 1 of at least 40%, is the reverse complement or the reverse of such sequences. In some aspects, the polynucleotide is linked to expression enhancers or sequences of interest. In some embodiments, a recombinant vector comprises the polynucleotide. In some aspects, the recombinant vector comprises enhancers, termination sequences, or sequences of interest. In some embodiments a transformed cell, plant, plant part, or propagulum comprise the polynucleotide.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: April 21, 2015
    Assignee: Empresa Brasileira de Pesquisa Agropecuaria
    Inventors: Maria Fatima Grossi de Sa, Luciane Mourao Guimaraes, Joao Aguiar Nogueira Batista, Antonio Americo Barbosa Viana, Rodrigo da Rocha Fragoso, Maria Cristina Mattar da Silva
  • Patent number: 9012617
    Abstract: Dual colored fluorescent indicators of specific tyrosine kinase activity and methods of use thereof are disclosed.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: April 21, 2015
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Matthew Dalva, Julia X. Zhu
  • Patent number: 9012721
    Abstract: The invention relates to transgenic plants with improved growth and nitrogen use efficiency expressing nitrate transporter gene, methods of making such plants and methods for improving growth and nitrogen use efficiency.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: April 21, 2015
    Assignees: Plant Bioscience Limited, Nanjing Agricultural University
    Inventors: Guohua Xu, Xiaorong Fan, Qirong Shen, Anthony Miller
  • Publication number: 20150106970
    Abstract: Provided is a breeding method for two lines hybrid rice based on the rice mutant osms4 (Oryza sativa male sterile 4), which was originally selected from the mutagenizing seeds of japonica cultivar 9522 with 60Co gamma ray, and the stable inheritance osms4 mutant was obtained after three generations backcrossing, which is regulated by a recessive single gene OsMS4. The invention is related to the usage of OsMS4 gene (also known as Carbon Starved Anther, the CSA gene), osms4 mutant can be used as male sterile line under short day condition in both japonica and indica background, which grows abnormal anther with defection during second mitosis stage and produces completely sterile pollen. While under the long day condition, the osms4 mutant can be used as maintainer liner and produces normal pollen.
    Type: Application
    Filed: November 29, 2010
    Publication date: April 16, 2015
    Applicant: SHANGHAI JIAOTONG UNIVERSITY
    Inventor: Dabing Zhang
  • Patent number: 9006412
    Abstract: An expression vector capable of expressing a foreign gene in Pseudonocardia autotrophica; a transformant of Pseudonocardia autotrophica produced by using the expression vector; a method for producing a protein by using the transformant; a method for producing an active form of vitamin D3 from vitamin D3, which comprises highly expressing a gene encoding an enzyme involved in the synthesis of the active form of vitamin D3 in a transformant by using the expression vector or the transformant; a method for producing 25-hydroxyvitamin D2 from vitamin D2; and a method for producing pravastatin from compactin, which comprises highly expressing a compactin hydroxylase gene in a transformant by using the expression vector or the transformant.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: April 14, 2015
    Assignees: Microbiopharm Japan Co., Ltd., National Institute of Advanced Industrial Science and Technology
    Inventors: Yoshikazu Fujii, Tadashi Fujii, Akira Arisawa, Tomohiro Tamura
  • Patent number: 9006518
    Abstract: Disclosed are genetic constructs, transgenic plant cells and transgenic plants, as well as associated methods, for increasing oil production in a plant using F-box gene sequences.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: April 14, 2015
    Assignee: Board of Trustees of Michigan State University
    Inventors: John B. Ohlrogge, Sari A. Ruuska, Yonghua Li
  • Patent number: 9005935
    Abstract: The present invention provides new compositions for transposase-mediated fragmenting and tagging DNA targets. The invention relates to the surprising discovery that use of manganese ions (Mn2+) in transposase reactions improves the transposase reaction. It also relates to the surprising discovery that Mg2+ ions can be used in a transposase reaction with wild-type and/or engineered transposases at levels much higher than previously thought. The invention provides for the use of naturally-occurring transposases in in vitro reactions, as well as improved schemes for cleaving, tagging, and amplifying target DNA.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: April 14, 2015
    Assignee: Agilent Technologies, Inc.
    Inventor: Alexander S. Belyaev
  • Patent number: 9006515
    Abstract: Compositions and methods for regulating expression of heterologous nucleotide sequences in a plant are provided. Compositions include nucleotide sequences encompasses a strong pollen preferred promoter which drives strong, specific expression of gene products in pollen. Also provided is a method for expressing a heterologous nucleotide sequence in a plant using a promoter sequence disclosed herein.
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 14, 2015
    Assignee: Pioneer Hi Bred International Inc
    Inventors: Andrew Mark Cigan, Shai J Lawit
  • Patent number: 9006413
    Abstract: Isolated polynucleotides comprising a PCP2 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, gene therapy, etc.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: April 14, 2015
    Assignee: The University of British Columbia
    Inventors: Elizabeth M. Simpson, Wyeth W. Wasserman, Robert A. Holt, Steven J. Jones, Daniel Goldowitz, Elodie Portales-Casamar, Cletus D'Souza, Vikramjit Chopra, Charles de Leeuw
  • Patent number: 8999673
    Abstract: Provided is a method for selectively obtaining, for a given target gene, a “joined DNA fragment” wherein just a target gene fragment is joined with desired other DNA fragments, regardless of whether a DNA fragment containing a target gene sequence has been purified. In the provided method, a double-stranded joining DNA fragment containing a sequence A and/or a sequence B is selectively joined to the ends of a target gene fragment. A mixture of a double-stranded gene fragment, the 3? end of which is protruding, and the double-stranded joining DNA fragment, which are related in a prescribed manner, undergoes at least two cycles of thermal denaturation, reassociation, and DNA synthesis, resulting in a “joined DNA fragment,” which is a double-stranded DNA fragment including at least one instance of a sequence resulting from joining sequence A, the target gene sequence, and sequence B. A “single-side joined DNA fragment” can also be obtained, by a similar method.
    Type: Grant
    Filed: September 2, 2010
    Date of Patent: April 7, 2015
    Assignee: National University Corporation University of Toyama
    Inventors: Nobuyuki Kurosawa, Masaharu Isobe
  • Patent number: 8999641
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 7, 2015
    Assignees: The Broad Institute Inc., Maassachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana
  • Patent number: 8999667
    Abstract: The invention provides a DNA molecule comprising a multicistronic transcription unit coding for i) a polypeptide of interest, and for ii) a selectable marker polypeptide functional in a eukaryotic host cell, wherein the polypeptide of interest has a translation initiation sequence separate from that of the selectable marker polypeptide, and wherein the coding sequence for the polypeptide of interest is upstream from the coding sequence for the selectable marker polypeptide in the multicistronic transcription unit, and wherein an internal ribosome entry site is present downstream from the coding sequence for the polypeptide of interest and upstream from the coding sequence for the selectable marker polypeptide, and wherein the nucleic acid sequence coding for the selectable marker polypeptide in the coding strand comprises a GTG or a TTG start codon. Also provided are methods for obtaining host cells expressing a polypeptide of interest, such host cells comprising DNA molecules of the invention.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: April 7, 2015
    Assignee: Chromagenics B.V.
    Inventors: Arie P. Otte, Theodorus H. J. Kwaks, Henricus J. M. van Blokland, Richard G. A. B. Sewalt
  • Patent number: 8993837
    Abstract: Compositions and methods comprising promoters from the 4-hydroxyphenylpyruvate dioxygenase (HPPD) gene and active variants and fragments thereof, as well as chimeric promoters employing regulatory regions of the HPPD promoters are provided. Further provided are expression cassettes and plants comprising the various promoters disclosed herein operably linked to a polynucleotide of interest. Methods employing the various promoters described herein to modulate the expression of polynucleotides of interest are further provided.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: March 31, 2015
    Assignee: Pioneer Hi-Bred International, Inc
    Inventors: Henrik Albert, Linda A. Castle, Jian Lu, Yumin Tao
  • Patent number: 8993233
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 31, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana, Fei Ran
  • Patent number: 8993840
    Abstract: This invention relates to polynucleotide sequences encoding SUT2 or SUT4 sucrose transporter genes. Methods for increasing seed oil content and evaluating increased oil content in a plant seed are described. The compositions and methods disclosed herein employ a variety of sequences that encode sucrose transporters and a variety of sequences that influence fatty acid accumulation, including for example, DGAT, Lec1 and ODP1 transcription factor. In specific embodiments, overexpression of SUT2 and/or SUT4 sucrose transporters in combination with DGAT genes further increase plant seed oil production compared to a high oil plant comprising recombinant DNA constructs that do not overexpress SUT2 or SUT4 transporters.
    Type: Grant
    Filed: November 1, 2010
    Date of Patent: March 31, 2015
    Assignee: E I du Pont de Nemours and Compay
    Inventors: Stephen M. Allen, Howard Glenn Damude, John D. Everard, Knut Meyer, Byung-Chun Yoo
  • Patent number: 8993836
    Abstract: The invention concerns tools, methods and compositions for modifying plants and/or protein expression in plants. The invention concerns in particular transcriptional promoters enabling specific expression in the trichomes, constructs containing said promoters, and their uses for genetically modifying cells, seeds or plants. The invention also concerns methods for producing transgenic plants expressing proteins or metabolites of interest. The invention is generally applicable to any plant having glandular trichomes, and to the expression of any protein of industrial interest, in particular therapeutic or phytosanitary.
    Type: Grant
    Filed: October 12, 2005
    Date of Patent: March 31, 2015
    Assignee: Philip Morris Products S.A.
    Inventors: Alain Tissier, Christophe Sallaud, Denis Rontein
  • Patent number: 8993861
    Abstract: The promoters of a soybean SC194 polypeptide and fragments thereof and their use in promoting the expression of one or more heterologous nucleic acid fragments in plants are described.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: March 31, 2015
    Assignee: E I du Pont de Nemours and Company
    Inventor: Zhongsen Li
  • Patent number: 8993238
    Abstract: Compositions and methods related to transgenic glyphosate tolerant Brassica plants are provided. Specifically, the present invention provides Brassica plants having a DP-073496-4 event which imparts tolerance to glyphosate. The Brassica plant harboring the DP-073496-4 event at the recited chromosomal location comprises genomic/transgene junctions within SEQ ID NO: 2 or with genomic/transgene junctions as set forth in SEQ ID NO: 12 and/or 13. The characterization of the genomic insertion site of the event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the event are provided.
    Type: Grant
    Filed: October 7, 2013
    Date of Patent: March 31, 2015
    Assignees: E I du Pont de Nemours and Company, Pioneer Hi Bred International Inc
    Inventors: David George Charne, Wenpin Chen, Chadwick Bruce Koscielny, Zhongsen Li, Jayantilal Patel, Ferdinand G Thoonen, Lomas Tulsieram, Yongping Zhang
  • Publication number: 20150087070
    Abstract: Synthetic, derivative promoters for expression of chimeric genes in Zymomonas, Zymobacter, and related bacteria were created. The promoters have a C to T change in the nucleotide at position 90 of the Z. mobilis glyceraldehyde-3-phosphate dehydrogenase gene promoter. Promoters with this change have higher expression as compared to the native promoter from which they are derived and are useful for genetic engineering for expressing coding regions or regulatory RNA to obtain high levels of expressed proteins or regulatory RNAs.
    Type: Application
    Filed: September 26, 2013
    Publication date: March 26, 2015
    Applicant: E I DU PONT DE NEMOURS AND COMPANY
    Inventor: JIANJUN YANG
  • Patent number: 8987434
    Abstract: The present invention relates to novel hybrid promoters comprising a caulimovirus promoter operably linked to one or more of an EF1?, Act8, Act2 or Act11 promoter. The present invention also relates to novel DNA constructs comprising at least one expression cassette which comprises the hybrid promoter thereof. The present invention further relates to transgenic plants/seeds comprising such DNA constructs.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: March 24, 2015
    Assignee: Monsanto Technology LLC
    Inventors: Karen L. Fincher, Stanislaw Flasinski, Jack Q. Wilkinson
  • Publication number: 20150080456
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Nuclear Respiratory Factor 1 (NRF1), in particular, by targeting natural antisense polynucleotides of Nuclear Respiratory Factor 1 (NRF1). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of NRF1.
    Type: Application
    Filed: November 18, 2014
    Publication date: March 19, 2015
    Inventors: Joseph COLLARD, Olga Khorkova Sherman
  • Patent number: 8980858
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Methionine Sulfoxide Reductase A (MSRA), in particular, by targeting natural antisense polynucleotides of Methionine Sulfoxide Reductase A (MSRA). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of MSRA.
    Type: Grant
    Filed: May 25, 2011
    Date of Patent: March 17, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman
  • Patent number: 8980862
    Abstract: Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 17, 2015
    Assignee: Gentium S.p.A.
    Inventor: Massimo Iacobelli
  • Patent number: 8980853
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: March 17, 2015
    Assignees: Isis Pharmaceuticals, Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
  • Patent number: 8980860
    Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Discs large homolog (DLG), in particular, by targeting natural antisense polynucleotides of Discs large homolog (DLG). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of DLG.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: March 17, 2015
    Assignee: CuRNA, Inc.
    Inventors: Joseph Collard, Olga Khorkova Sherman, Carlos Coito
  • Patent number: 8980556
    Abstract: Compositions and methods for determining an increased likelihood of a response to a targeted treatment of a cancer disease including isolating genomic DNA from a patient sample, amplifying a fragment of DNA by means of PCR with a specific pair of amplification primers, determining if the amplified fragment comprises a wildtype sequence or a mutation by means of a High Resolution Melting Analysis (HRM), and correlating the presence or absence of a mutation with an increased likelihood of success of said targeted treatment. Respective primer pairs, compositions and kits are also claimed.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: March 17, 2015
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Reinhard Buettner, Stefanie Froehner, Sabine Merkelbach-Bruse, Jasmin Ney, Angelika Roesler
  • Publication number: 20150071901
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and/or improving the specificity of RNA-programmable endonucleases, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off” state, which control the binding and hence cleavage activity of RNA-programmable endonucleases. Some aspects of this disclosure provide mRNA-sensing gRNAs that modulate the activity of RNA-programmable endonucleases based on the presence or absence of a target mRNA.
    Type: Application
    Filed: July 8, 2014
    Publication date: March 12, 2015
    Applicant: President and Fellows of Harvard College
    Inventors: David R. Liu, Johnny Hao Hu
  • Publication number: 20150071902
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and/or improving the specificity of RNA-programmable endonucleases, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off” state, which control the binding and hence cleavage activity of RNA-programmable endonucleases. Some aspects of this disclosure provide gRNAs that modulate the activity of an RNA-programmable endonuclease based on the presence or absence of an extended DNA (xDNA).
    Type: Application
    Filed: July 8, 2014
    Publication date: March 12, 2015
    Applicant: President and Fellows of Harvard College
    Inventors: David R. Liu, Johnny Hao Hu
  • Patent number: 8975023
    Abstract: The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: March 10, 2015
    Assignees: Amino Up Chemical Co., Ltd, Kansai Medical University
    Inventors: Tadayoshi Okumura, Mikio Nishizawa, Yasuo Kamiyama, Koji Wakame, Takehito Miura
  • Patent number: 8975391
    Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: March 10, 2015
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventor: Barbara Enenkel
  • Patent number: 8975472
    Abstract: Preparation and use of isolated nucleic acids useful in altering the oil phenotype of plants are described. Isolated nucleic acids and their encoded polypeptides are described that alter the content of alpha-tocotrienol, beta-tocotrienol, or both, in transformed seeds and oil obtained from the transformed seeds. Expression cassettes, host cells and transformed plants are described that contain the foregoing nucleic acids.
    Type: Grant
    Filed: January 3, 2013
    Date of Patent: March 10, 2015
    Assignee: E I du Pont de Nemours and Company
    Inventor: Knut Meyer
  • Patent number: 8969539
    Abstract: This present invention provides an expression vector system that uses alternative RNA processing to express in a single cell a polypeptide in both membrane-bound and soluble forms. By incorporating a mimetic structure of the 3? terminal region of human mu gene and introducing other exogenous genetic elements, an artificial gene can be constructed that is capable of simultaneously expressing membrane-bound and secreted forms of polypeptides in myeloma cells and other cells of the B lymphocyte lineage, as well as in non-B cells. If an immunoglobulin heavy chain is co-expressed with a light chain using this vector, whole antibodies can be produced that are both displayed on the surface of a single cell and secreted into the cell culture supernatant. Membrane-bound antibodies facilitate isolation and expansion of those cells displaying antibodies with desired antigen binding characteristics, while secreted antibodies facilitate identification of antibodies having desired biological function(s).
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: March 3, 2015
    Assignee: JN Biosciences LLC
    Inventors: Naoya Tsurushita, J. Yun Tso
  • Patent number: 8969316
    Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: March 3, 2015
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
  • Publication number: 20150057155
    Abstract: The present invention relates to novel hybrid promoters comprising a caulimovirus promoter operably linked to one or more of an EF1?, Act8, Act2 or Act11 promoter. The present invention also relates to novel DNA constructs comprising at least one expression cassette which comprises the hybrid promoter thereof. The present invention further relates to transgenic plants/seeds comprising such DNA constructs.
    Type: Application
    Filed: July 29, 2014
    Publication date: February 26, 2015
    Inventors: Karen L. Fincher, Stanislaw Flasinski, Jack Q. Wilkinson